Iodophenpropit dihydrobromide

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Additional Information

Background References

1. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death.
   Fox JT, Sakamuru S, Huang R
   Proc. Natl. Acad. Sci. U.S.A., 2012;109(14):5423-8.
2. Assessment of [125I]WYE-230949 as a novel histamine H3 receptor radiopharmaceutical.
   Lewis, David Y, Champion, Sue, Wyper, David, Dewar, Deborah, Pimlott, Sally
   PLoS ONE, 2014;9(12):e115876.
3. Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent.
   Tollefson and Taylor
   CNS Drug Reviews, 2000;6:303
4. The first radiolabelled histamine H₃ receptor antagonist, [¹²⁵I]iodophenpropit: saturable and reversible binding to rat cortex membranes.
   Jansen et al.
   Eur.J.Pharmacol., 1992;217:203
5. Characterisation of the binding of the first selective radiolabelled histamine H₃ receptor antagonist, [¹²⁵I]-iodophenpropit, to rat brain.
   Jansen et al.
   Br.J.Pharmacol., 1994;113:355
6. Synthesis of S-[3-(4(5)-imidazolyl)propyl]-N-[2-(4-[¹²⁵I]-iodophenylethyl]isothiourea sulfate [¹²⁵I]-iodophenpropit), a new probe for histamine H₃ receptor binding sites.
   Menge et al.
   J.Labelled Comp.Radiopharm. XXXI, 1992;10:781
7. Histamine, histamine receptors, and their role in immunomodulation: An updated systematic review.
   Shahid et al.
   Open Immunol.J., 2009;2:9

Product Datasheets